SUSMED,Inc. (TYO:4263)
Japan · Delayed Price · Currency is JPY 470.00
-99.00 (-17.40%)
Aug 27, 2026, 11:30 AM JST
SUSMED,Inc. Revenue
In the fiscal year ending June 30, 2026, SUSMED,Inc. had annual revenue of 497.00M JPY with 7.58% growth. SUSMED,Inc. had revenue of 267.00M in the quarter ending June 30, 2026, with 506.82% growth.
Revenue
497.00M
Revenue Growth
+7.58%
P/S Ratio
19.25
Revenue / Employee
n/a
Employees
43
Market Cap
9.57B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 497.00M | 35.00M | 7.58% |
| Jun 30, 2025 | 462.00M | 120.00M | 35.09% |
| Jun 30, 2024 | 342.00M | -188.00M | -35.47% |
| Jun 30, 2023 | 530.00M | 214.00M | 67.72% |
| Jun 30, 2022 | 316.00M | 201.00M | 174.78% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 6.14B |
| CellSource | 3.67B |
| StemCell Institute | 2.81B |
| Immuno-Biological Laboratories | 1.08B |
| OncoTherapy Science | 777.00M |
| Carna Biosciences | 729.00M |
| Nano Holdings | 202.00M |
| CellSeed | 161.00M |